initi coverag
initi coverag life scienc diagnost tool sector
demand acceler across univers yet valuat extend leav
investor us grappl assess invest opportun
messag expect strong fundament continu
improv growth modest compani fewer valuat
dispar select key stock select approach bottom
address pivot industri question help inform rate
biopharma demand sustain high singl digit growth china opportun
risk impact macro contract research growth
rebound data-driven recruit capabl real differenti
tool diagnost pharma servic takeaway
tool diagnost end market robust view biopharma key driver
outlook improv buy sell china tariff risk look manag
deter secular demand end market remain fragment
recommend own acquir buy find differenti leader
big market buy pharma servic clinic trial demand acceler
though penetr headroom mute buy data-driven recruit
critic custom take note buy sell iclr
proprietari dilig robust
glassdoor review googl trend analysi eight transcriptlyt report
supplement extens number expert call plu incorpor insight
equiti strategi econom team china tariff scenario analysi
launch life scienc diagnost tool buy neutral sell
buy-rat stock neutral rate
 sell rate iclr
report prepar ub secur llc analyst certif requir disclosur begin
page ub seek busi compani cover research report result investor
awar firm may conflict interest could affect object report investor consid
report singl factor make invest decis
focu
tool end market robust biopharma growth driver
buy rapid biopharma growth drive re-rat
sell lack biopharma exposur limit growth
tool outsiz china exposur revenu sector growth
tariff manag risk secular trend look great
tool industri consolid invest buy acquir
see materi ep upsid buy
diagnost find differenti leader big market
 buy share market growth inflect
pharma servic strong cro fundament best data strategi win
buy growth acceler driven clinic trial offer key
iclr sell contrarian call expect futur share loss lack in-hous data capabl
buy contrarian call busi improv cheap part
product cycl stori posit ub evid lab survey rate neutral
 novaseq demand better expect valuat price neutral
sculpsur market growth contract risk growth profil neutral
factset ub research price octob
rare disloc valu name sector
data-driven patient recruit drive share gain
best way tool play biopharma growth theme
improv growth profil biggest stock driver
pharma exposur balanc sheet limit margin
growth inflect stock reflect
consist share gainer struggl find true differenti
evid strong growth limit margin upsid
recov still overhang
ub evid lab confirm novaseq open larg new market
superior oper perform alreadi reflect valuat
risk share loss data-driven recruit strategi
under-exposur biopharma end market rel disadvantag
differ current price
tool biopharma demand sustain
tool china opportun risk
tool macro sensit group call
pharma servic contract research growth rebound weak
pharma servic data-driven patient recruit capabl real
later cycl
end market robust theyv
long time
valuat extend
vc fund record level
clinic penetr high
valuat get extend
margin expans harder gener
price ration
scienc pipelin
industri becom competit
function servic grow mix
evid extens
cologuard survey
transcriptlyt report four stock
expert call across europ china
separ ub evid lab survey show biopharma acceler
budget acceler
acceler
drug pipelin shift toward biolog long-term
trend inform stock select
patient recruit score better iclr
rate vendor approach patient recruit
made call bottom vs top
bottom
identifi key driver go deep get edg
evalu upsid opportun versu downsid risk
top
focus top custom end market trend
rel posit compani share gainers/los
macro pay attent main driver call
differ consensu
revenu growth import metric
stock sector histor expens
 ev sale dev
 ev sale std dev
factset consensu ub research
perform sector outperform
tool outperform year
pharma servic outperform year
good busi esp tool
threat new entri
tool moder
tool moder
threat substitut
tool sector grown nomin global
past decad
tool consist expand margin faster
factset compani data ub research
messag acceler organ growth expect driven robust industri
demand china biopharma custom growth plu upsid
biopharma spend life scienc yy go
biolog product spend yy
organ growth consensu
 ep upsid see next year
china risk reward china compound-annual-growth-rate driven growth
valuat dcf impli ntm price-to-earnings rel vs current
rel year averag ntm price-to-earnings rel
messag stock lag life scienc peer sinc jan expect
recent momentum continu growth acceler gap vs life scienc peer
close consensu model growth deceler expect recent
improv sustain dental spin catalyst
thesi recent upturn growth sustain
upsid signific accret price
driver better trend pall beckman strength bioproduct recent
deal cphd mostli key
china risk reward less expos
valuat dcf impli ntm price-to-earnings rel vs current
messag expect acceler growth ahead consensu enabl
differenti patient recruit offer robust industri fundament drive
stock higher multipl re-rat recogn
thesi share gain strong market growth support cro segment
growth acceler ahead consensu
driver uptak data-driven patient recruit offer
clinic budget acceler
share gainer rank data-driven enrol strategi
 analyt ebitda improv support price-to-earnings expans
valuat dcf pt impli ntm pe rel vs current
messag market valu like tarnish asset clinic market
robust respect particip commerci busi grow
market valu flat accord revers dcf
thesi clinic growth acceler commerci growth turn posit
would narrow discount sotp fair valu
clinic budget acceler
commerci penetr increas bp per year next three year
ub estim organ growth vs consensu
sotp analysi show current valuat discount fair valu
risk deterior commerci share shift data-driven strategi
messag new relationship acceler frequenc doc order key
toward revenu acceler revenue forecast consensu
thesi penetr co-promot acceler test
doctor network success deal re-test opportun cohort upsid
current/futur cologuard usag recent result street forecast
tests/doctor survey current actual model
cologuard market share survey current current penetr
metric test per doc acceler revenu
pipelin upsid
valuat dcf-base pt impli penetr
messag stock pois move higher market come appreci
bullish view digit spatial profil dsp product differenti
commerci opportun ramp dsp contribut growth
thesi robust dsp growth account continu moder
base ncounter busi enabl grow thru
driver dsp commerci launch instrument placement ramp consum pull
thru maintain flattish ncounter placement declin pull thru
evid numer call kol clinical/transl market regard
spatial profil current landscap futur need dilig kol
rnaseq price declin par ncounter
declin creat pressur
risk dsp execut risk scale commerci product dsp demand
messag inferior growth profil due low biopharma exposur drag
nmr nuclear magnet reson revenu modest ramp
new invest project acceler expect growth margin consensu
new product margin analysi impli expans guidanc
capit equip risk slowdown outsiz eu exposur china
risk new product upsid restructur nmr backlog
ntm price-to-earnings rel averag rel
messag stock trade near decade-high multipl market
like expect sustain growth beyond expect downsid
market share shift caus growth deceler
thesi growth weaken custom shift data-driven enrol strategi
driver iclr recruit strategi inferior lead share loss
reli physic parti trial site find/enrol patient trial get weaker score
leader million patient record mine identifi
effici enrol monitor clinic trial
limit margin street
risk could earli strong market backdrop
lab incl hi seq
repres hi seq custom
base hi seq
nova actual
expect acceler spend
cut increas manag need
monitor
topic novaseq demand impact
led averag yy declin
sculpsur cynosur revenu
sculpsur share flat around
sculpsur use salesforc
issu fix issu
neutral stock cheap
cynosur recoveri
growth profil bare big
one liner remain stock
growth turn biopharma key b/ ceo posit margin limit
manag expect growth rate tripl see doubl
premium growth rate risk
demand backdrop robust margin expans limit
growth driver biolog acceler weak softgel trend issu
ub research
day
biopharma end market growth
sustain mid-to-high singl digit
biopharma largest custom averag
biopharma largest contributor growth
pharma growth faster end
biopharma contribut core growth
despit revenu sector
biopharma growth strong
drug pipelin grow sinc
biolog grow pipelin mix
chang method reduc growth
biopharma growth strong cont
fda approv robust shift biolog
biopharma growth strong cont
vc fund record level
ipo follow-on biopharma
number vc deal
biopharma lab survey show acceler
equip consum budget
total budget
total life scienc equip consum budget
ub evid lab survey repres outlook key
respond manag
respond work
europ
direct control influenc budget
 budget survey spent instrument
consum
direct control
budget decis awar
specif purchas decis
influenc
budget decis awar
specif purchas decis
knowledg
budget decis awar
specif purchas decis
ub evid lab
growth major tool instrument class
expos right area biopharma
import growth best posit
china opportun
risk tool
china critic geographi tool
revenu exposur china much higher
china revenu grown faster growth
total revenu sector
compani data ub research
china import contributor revenu growth
tool compani
pharma china grow
research fund grow faster nih
china pace invest
chines public spend life scienc
grown much faster nih
ub research unesco
china opportun china five-year
align life scienc
increas spend
increas contrib science/tech econ growth
contribut science/tech econ growth
incresas citat science/tech journal
increas popul scientif degre
chang carbon dioxid emiss intens
surfac water meet/exce class rate
surfac water meet/exce class iv rate
 -china econom secur review commiss ub research
us import china
impact product relev lst
effect
comput peripher equip mfg misc mfg semi electron
effect
effect
comput peripher equip mfg misc mfg semi electron plastic
product mfg electr equip compon mfg gener purpos
product mfg glass glass product mfg
us export china
effect
effect
impact product relev lst
basic chemic manufactur resin synthet rubber etc medicin
manufactur plastic product manufactur oil ga extract
machineri electr eqpt plastic chemicals/rubb
stock under-perform china worri despit
compani say tariff mostli
yet high-china stock
tariff risk manag base scenario
ep impact gdp-sensit
compani
scenario
addit tariff
us-china trade
scenario tariff
virtual us/china trade
macro sensit group
call
tool healthcar sector signific
exposur macro-sensit end market
tool sector expos end market econom sensit healthcar
compani sensit
other mostli function industri exposur
r-squar core revenu growth versu real
ub growth estim bullish
fundament contract
research cro market rebound
anticip cro market growth
cro market expect rebound
hit low
merger larg trial cancel
affect growth
budget growth acceler
expect budget growth
augment increas
outsourc budget less
increas penetr current
driver cro revenu growth book-to-bil still
bogey convers rate declin
industri book-to-bil continu hover around
backlog convers rate continu long-
restat upward new
polic im merger
biopharma growth acceler
pharma outsourc survey show acceler
clinic budget growth expect
confirm separ biopharma lab survey show
acceler equip consum budget
total life scienc equip consum budget
ub evid lab
clinic penetr increas expect slow
outsourc budget may rise
clinic penetr increas expect slow
outsourc budget room rise
get budget growth
cro market growth reli
budget becom
nuanc point outsourc
penetr expect
increas outsourc budget
may increasejust
penetr today higher
penetr consist
outsourc budget
flat long expans
clinic coverag
near-term weaker usd help
margin ep clinic
servic work modest risk
execut
larg merger take margin debat
spotlight
ub evid lab suggest worri
price becom less import reput
relationship remain import
survey respond balanc
view price expect chang
know
avail capac abil start studi
price studi cost
size scale vendor
vendor reput servic qualiti
exist relationship vendor
alreadi prefer vendor
expect dramat
increas hourli rate
pay clinic trial work
expect modestli increas
hourli rate pay
expect littl chang
hourli rate pay
tri modest reduc
hourli rate pay
tri dramat
reduc hourli rate pay
clinic trial work
know
ub evid lab survey say readi
bear execut risk fix price
respond believ assum littl risk
describ attitud toward execut risk born
cro partner
respond expect increas use
assum littl
execut risk mani
chang order thing
cro foreseen
plan
assum fair amount
order happen due
inher uncertainti
assum larg amount
order limit
cro absorb
chang scope
know
intend dramat
increas use fix price
intend modestli increas
use fix price
anticip littl
chang use fix
intend modestli reduc
use fix price
intend dramat
reduc use fix price
know
ub evid lab
drive share-shift clinic contract
technolog becom import differenti
cro
respond say clinic trial technolog
becom import past year
respond say technolog critic
valu clinic trial
technolog becom
import past year
valu clinic trial
technolog chang
past year
valu clinic trial
technolog becom less
import past year
critic compon
view clinic trial
focu overal cro
ub evid lab
patient recruit import function
technolog lead
recruit import
function technolog best
worst
highest best worst
respond use
nextgen solut like
room awar
rate vendor approach patient recruit
extrem differenti
differenti worthwhil
unfamiliar
unclear need understand
ub evid lab
quarterli book-to-bil improv sinc
ub evid lab provid research analyst rigor primari research team
conduct repres survey key sector decision-mak mine internet systemat
collect observ data pull inform innov sourc appli
varieti advanc analyt techniqu deriv insight data collect valuabl
resourc suppli ub analyst differenti inform support forecast
recommendationsin turn enhanc abil serv need client
biopharma lab ub evid lab conduct on-line survey lab execut
work within biotechnolog biopharmaceut pharmaceut
compani respond mix compani without
commerci product major base us remain
base europ primarili uk germani spain
pharma outsourc ub evid lab conduct on-line survey pharma biotech
execut control discoveri preclin clinic clinic trial suppli budget
major respond manager/director level remain
vice-president svp c-suit level respond align mix therapeut area
strong represent oncolog cv immunolog infecti diseas inflamm
diabetes/metabol diseas half respond compani headquart
us hq europ japan remain region
aesthet ub evid lab conduct on-line survey plastic/cosmet surgeon
plastic surgeon cosmet dermatologist cosmet surgeon esthet practition
gener derm respond survey perform non-invas fat reduct
practic practition practic practition averag
year practic
cologuard ub evid lab conduct on-line survey physician
gastroenterologist see averag patients/month major physician
respond survey work independ own remain
practic own hospital/health system respond across mix
practic size small larg group practic
sequenc ub evid lab conduct on-line survey sequenc lab technician
us europ current next gener sequenc equip
authority/influ sequenc equip purchas half respond
core sequenc facil anoth biotech/pharma lab
academ lab remain clinic diagnost lab commerci sequenc lab
initi coverag life scienc diagnost tool octob
valuat method risk statement
tool compani industry-wid risk includ declin spend
pharmaceut compani due signific declin fund small
compani promin trial failur affect class drug revers
trend toward outsourc penetr greater price pressur
foreign exchang fluctuat chang tax polici
pharma servic industry-wid risk includ declin spend
pharmaceut compani due signific declin fund small
compani promin trial failur affect class drug deceler
global growth includ risk escal trade tension pressur
academ govern budget could result recessionari cost-
cut polit chang price pressur diagnost sector due
protect access medicar act pama chang competit
dynam includ disrupt new entrant certain technolog inabl
compani compet effect china critic growth market foreign
exchang fluctuat chang tax polici
initi coverag life scienc diagnost tool octob
